Drug adverse events associated with temozolomide administration: A real-world pharmacovigilance study using the FAERS database from 2014 to 2024
Journal of Oncology Pharmacy Practice
Published online on June 26, 2025
Abstract
Journal of Oncology Pharmacy Practice, Ahead of Print.
BackgroundTemozolomide, an alkylating agent with antitumor effects, is commonly used to treat newly diagnosed glioblastoma multiforme (GBM) and recurrent or progressive GBM or anaplastic astrocytoma. As its usage has increased, so have reports of ...
BackgroundTemozolomide, an alkylating agent with antitumor effects, is commonly used to treat newly diagnosed glioblastoma multiforme (GBM) and recurrent or progressive GBM or anaplastic astrocytoma. As its usage has increased, so have reports of ...